Effects of Antimicrobial Combinations on *Pseudomonas aeruginosa*-Aspergillus fumigatus Mixed Microbial Biofilm

**Abstract**

**Objectives:** Co-infection with *P. aeruginosa* and *A. fumigatus* is frequently seen in patients with cystic fibrosis. These microorganisms are known to produce biofilm both in vitro and in vivo. The biofilm-embedded microbial cells are frequently refractory to conventional antimicrobial therapy. The primary objective of this study was to evaluate the efficacy of several anti-pseudomonal antimicrobials such as cefepime, imipenem and ciprofloxacin individually and in pair-wise combinations with antifungal drugs on *P. aeruginosa*-A. *fumigatus* polymicrobial biofilm and compare the results with those obtained in monomicrobial biofilm.

**Methods:** Biofilms of *P. aeruginosa* and *A. fumigatus* isolates were grown in 24-well cell culture plates in Sabouraud’s dextrose broth at 35 °C. The activities of cefepime, imipenem and ciprofloxacin alone and in two-drug combination with voriconazole, posaconazole, amphotericin B and anidulafungin on monomicrobial and polymicrobial biofilms, as well as on planktonic cells were examined by CFU assay.

**Results:** Scanning electron microscopic studies showed that *A. fumigatus* produced firmly adherent mixed microbial biofilm with *P. aeruginosa* on ThermaCoat plastic coverslips with increased synthesis of extracellular matrix in the presence of the bacterial cells. The fungal hyphae in monomicrobial and polymicrobial biofilms were realigned during biofilm growth forming parallel-packed bundles with no apical or dichotomous branching. Typically, *P. aeruginosa* produced firmly adherent mixed microbial biofilm with increased synthesis of extracellular matrix in the presence of *A. fumigatus* hyphae, but tended to form loosely adherent monomicrobial biofilm. Overall, the susceptibility of *P. aeruginosa* to cefepime and imipenem alone and in pair-wise combination with antifungal drugs was significantly decreased in polymicrobial biofilms (≈0 to 0.5 logs CFU reduction at 16µg/ml) when compared to monomicrobial biofilms (≈1.5 to 4.5 logs CFU reduction at 16µg/ml) (*p* values ranged from 0.0076 to 0.0509). On the other hand, the efficacy of ciprofloxacin in monomicrobial and polymicrobial biofilms was similar (≈2.5 to 3.5 logs CFU reduction at 16µg/ml). *A. fumigatus* monomicrobial and polymicrobial biofilms were similarly susceptible to antifungal drugs with and without the antibacterial in the combination. Time-kill experiments performed at 4 times the MICs of the drugs (0.5µg/ml to 4µg/ml) showed that the planktonic cells of *P. aeruginosa* (≈4 to 4.5 logs CFU reduction) and *A. fumigatus* (≈2.5 to 3 logs CFU reduction) in monocultures and mixed microbial cultures were similarly susceptible to antifungal drugs.

**Conclusions:** In our model, the *P. aeruginosa* cells associated with *P. aeruginosa*-A. *fumigatus* polymicrobial biofilms were recalcitrant to certain antibacterial drugs compared to monomicrobial biofilms, whereas the planktonic cell monocultures and mixed microbial cultures showed no significant difference in their antimicrobial drug susceptibility profiles.

**Keywords:** Polymicrobial biofilm; Drug combinations; Differential activity; Antimicrobial drugs; Drug susceptibility

**Introduction**

Application of metagenomics [1-5] and high-resolution culture independent molecular probing techniques [6-10] have revealed that the microbiota of the airways of cystic fibrosis (CF) patients is highly complex and consists of 100s of microorganisms belonging to a wide variety of taxonomic groups. The pulmonary function of CF patients is significantly affected by the interaction of these microorganisms in the respiratory tract and by the proinflammatory host immune response generated against the airway microbial community. Furthermore, application of conventional culture dependent methods have identified a core group of bacterial pathogens consisting of *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Haemophilus influenzae*, *Burkholderia cepacia* complex, *Alcaligenes xylosoxidans* and *Stenotrophomonas maltophilia* [11-13] colonizing/infecting the airways of CF patients in an age
Effects of Antimicrobial Combinations on Pseudomonas aeruginosa-Aspergillus fumigatus Mixed Microbial Biofilm

In the bacterial species, the microbiota of CF airways often consists of fungi such as *Aspergillus fumigatus* [16,21], *Candida* species [22-26], *Scedosporium* species [27-30], *Exophiala dermatitides* [31-34] and *Pneumocystis* species [35-38], mostly in combination with bacteria producing mixed microbial colonization/infections in the CF airways [39]. The bacterial and fungal species more frequently isolated from the airway secretions of CF patients with mixed microbial colonization/infections are *P. aeruginosa* and *A. fumigatus*. These opportunistic pathogens frequently produce monomicrobial and polymicrobial biofilms both *in vitro* [40], and *in vivo* [41]. Genesis, architecture and drug susceptibility of *in vitro* and *in vivo* monomicrobial biofilms of *P. aeruginosa* have been the subject of investigation over the past two decades [42-44]. It has been shown that the biofilm-bound *P. aeruginosa* cells are highly tolerant/resistant to antimicrobial drugs [45-50] compared to their planktonic counterpart. However, to date very little is known about the development, structure and the effectiveness of antimicrobial drug treatment against the *P. aeruginosa-A. fumigatus* (Pa/Af) polymicrobial biofilm complex produced by mixed cultures of these microorganisms. More recently, *A. fumigatus* *in vitro* and human bronchial epithelial cell culture monomicrobial biofilm models were described to study the susceptibility of biofilm-associated fungal cells to antimicrobial drugs [51-53]. We recently described an *in vitro Pa/Af* polymicrobial biofilm model for studying the antimicrobial drug susceptibility of this mixed microbial biofilm [40]. Our preliminary study showed that the drug susceptibility of *A. fumigatus* to the triazoles such as voriconazole and posaconazole remained the same both in monomicrobial and polymicrobial biofilms, whereas the susceptibility of *P. aeruginosa* to ceftazidime was significantly reduced in polymicrobial biofilm compared to that of monomicrobial biofilm. However, the efficacy of tobramycin was unchanged in the polymicrobial biofilm vs monomicrobial biofilm. This difference in antibacterial activity against biofilms prompted us further study the antimicrobial susceptibilities of monomicrobial and polymicrobial biofilms of Pa/Af.

Thus, the primary objective of this study was to expand on our previous preliminary observations describing the differential susceptibilities of *P. aeruginosa* to ceftazidime in monomicrobial and polymicrobial biofilms by including additional antimicrobial drugs and isolates of *P. aeruginosa* and *A. fumigatus*. The key question was whether the formation of a mixed microbial biofilm provides added protection to either the bacterial or the fungal cell from the effects of antimicrobial drugs alone or in combinations when compared to the effects on monomicrobial biofilms produced by *P. aeruginosa* and *A. fumigatus*. The in vitro effectiveness of individual and pair-wise combinations of the drugs was examined by determining the reduction of CFU after a 24h exposure to the drug(s).

**Materials and Methods**

**Microorganisms:** *P. aeruginosa* isolates 56402 (PA56402: a multidrug-resistant clinical isolate obtained from the Microbiology Laboratory of Henry Ford Hospital in Detroit, MI, USA), PA01 (obtained from Matthew Parsek, University of Washington, Seattle, WA, USA) and *P. aeruginosa* 27853 (PA27853: American Type Culture Collection, Manassas, VA, USA) were used in this study. The cultures preserved as freezer stocks in -80 °C were subcultured on Brain Heart Infusion (BHI) agar for the evaluation of purity and viability. Working cultures were routinely grown on BHI agar, stored at 4 °C and sub-cultured once a week to maintain viable stock cultures. PA56402, PA01 and PA27853 were susceptible to a variety of antibacterial drugs such as aminoglycosides, β-lactams and fluoroquinolones, including cefepime (MIC ≤1µg/ml), imipenem (MIC ≤2µg/ml) and ciprofloxacin (MIC ≤0.25 µg/ml). Sabouraud’s dextrose (SD) agar and SD broth were used for growing monomicrobial and mixed microbial cultures producing biofilms. One ml aliquots of the overnight cultures were centrifuged in a microcentrifuge at top speed for 2min and the pellets washed 3 times with sterile distilled water, resuspended in 1 ml fresh SD broth, standardized spectrophotometrically using a standard curve, and then used for the various experiments. The use of SD agar and SD broth was particularly convenient since these media were commonly used to grow *A. fumigatus*.

The *A. fumigatus* clinical isolates 53470 and 43135 (AF53470 and AF43135) obtained from the Microbiology Laboratory of Henry Ford Hospital in Detroit, Michigan, USA and ATCC 36607 (AF36607) purchased from American Type Culture Collection were used in this study. The initial cultures were subcultured on SD agar to evaluate viability and purity of the culture, and subsequently stored as conidial suspension in 25% glycerol at -80 °C. Working cultures were maintained on SD agar plates at 4 °C. AF53470, AF43135 and AF36607 were all susceptible to polyenes, triazoles and echinocandins, including amphotericin B, voriconazole, posaconazole (MICs 1µg/ml, 0.25µg/ml, 0.125µg/ml, respectively) and anidulafungin (minimum effective concentration 0.031µg/ml). For preparation of conidia, cultures were grown on SD agar plates for 4 days at 35 °C to produce conidia. The SD agar containing mycelial growth was cut into small (5 mm²) pieces using a sterile spatula, transferred to a 50-ml screw-capped conical culture tube containing 25 ml sterile distilled water and vortexed vigorously for 2 min to disperse the conidia from the conidiophores. The resulting fungal suspension was filtered through 8 layers of sterile cheese cloth to remove mycelial and agar debris. The clarified conidial suspension thus obtained was standardized by hemocytometer count and stored at 4 °C in the refrigerator.

**Scanning Electron Microscopy:** The monomicrobial and polymicrobial biofilms of *A. fumigatus* and *P. aeruginosa* were grown on sterile tissue culture Thermofix 13mm plastic coverslips (Nalgene Nunc International, Rochester, NY, USA) in SD broth at 35 °C. For the development of polymicrobial biofilm, sterile plastic coverslips were placed in 12-well Costar tissue culture plate and 2ml *A. fumigatus* conidial suspension (1x10⁶ conidia/ml) was placed in each well completely covering the submerged plastic cover slips. The tissue culture plate with the cover slips was incubated statically at 35 °C for 18h for the conidia to germinate and form a monolayer of mycelial growth on the plastic coverslips. The spent growth medium from each well was removed and the mycelial growth was washed 3 times with sterile distilled water.
Effects of Antimicrobial Combinations on Pseudomonas aeruginosa-Aspergillus fumigatus Mixed Microbial Biofilm

(2ml each) and inoculated with 2ml SD broth containing 1x10⁶ P. aeruginosa cells/ml. The mixed culture was incubated for 24 h at 35 °C for the development of polymicrobial biofilm. The plastic cover slips containing the mixed microbial growth were washed 3 times with sterile distilled water (2ml each) and transferred to a clean 12-well Costar tissue culture plate and the biofilm was fixed for 60 min in 2% glutaraldehyde in 0.1M sodium cacodylate (NaCac) buffer (pH 7.4), postfixed in 2% osmium tetroxide in NaCac buffer, dehydrated with a graded ethanol series (25-100%) and critical point dried in CO₂. The dried specimens were mounted on aluminum stubs with carbon adhesive tabs and sputter coated with gold-palladium. Biofilm was observed and imaged in a FEI XL30 scanning electron microscope (FEI, Hillsboro, OR) at 10 kV. For the development of monomicrobial biofilms A. fumigatus and P. aeruginosa, monocultures of these organisms were grown on Thermaox coverslips for 24 h at 35 °C, washed and processed for SEM as described above. The images were edited and processed using SPOT image processing computer software [54].

**Determination of the effects of antibiotics on biofilms: A. fumigatus conidia (1x10⁶ conidia/ml) were grown in 1ml SD broth in Costar 24-well cell culture plates at 35 °C for 18h.** The surface growth was removed and the adherent mycelial growth on the bottom of the plastic well was washed 3 times with sterile distilled water (1ml each) and inoculated with 1x10⁶ P. aeruginosa cells in 1ml SD broth, and incubated at 35 °C for 24h for the development of polymicrobial biofilms. Monocultures of P. aeruginosa and A. fumigatus were grown under identical conditions for the formation of monomicrobial biofilms. The biofilms were washed with distilled water (3 times, 1ml each) and incubated with the required concentrations of antimicrobial drug(s) for 24h at 35 °C. The drug-treated biofilms were washed and the adherent cultures containing either fungal or bacterial or a mixed population of fungal and bacterial cells were harvested by scraping the bottom of the wells of the cell culture plate using sterile swabs into 1ml aliquots of sterile distilled water. The cell suspension was vortexed vigorously to disperse the cells, diluted 10 to 10⁶ fold and 0.01 ml aliquots of the cell suspensions were plated on ciprofloxacin (50µg/ml) or voriconazole (16µg/ml) containing SD agar plates and incubated at 35 °C for 24h for selective growth. The number of CFU for each group was determined and plotted against the drug concentration to assess the effectiveness of antibiotic treatment against biofilms.

**In vitro Susceptibility:** The in vitro susceptibility of P. aeruginosa isolates to various antibacterial drugs listed in Table 1 was initially examined using the fully automated Vetek 2 system (bioMérieux, Inc., Durham, NC, USA) and subsequently confirmed for cefepime, imipenem and ciprofloxacin in our laboratory using CLSI Protocol M100-S19 [55]. Susceptibility testing with cefepime, imipenem and ciprofloxacin was repeated at least once and the results were identical.

The in vitro susceptibility of AF53470, AF43135 and AF36607 to voriconazole, posaconazole, amphotericin B and anidulafungin was determined by CLSI Document M38-A2 [56]. Drug concentrations ranging from 0.031µg/ml to 16µg/ml were used. The MICs of voriconazole, posaconazole and amphotericin B were defined as the lowest concentration of the drug that provided 100% growth inhibition whereas the effectiveness of the echinocandin was defined as the lowest concentration of the drug that produced a distinct morphological change (minimum effective concentration) resulting in granular appearance of the colony due to stunted mycelial growth. Each susceptibility test was repeated at least once and the results were either identical or ± one two-fold dilution.

**Determination of bactericidal and fungicidal effects on suspension cultures:** The fungicidal and bactericidal activities of various antifungal and antibacterial drugs alone and in two-drug combinations on monomicrobial and polymicrobial cell suspensions were examined by determining the microbicidal activity of the drug(s). Overnight cultures of P. aeruginosa isolates PA56402, PA01 and PA27953 were grown in 5ml SD broth at 35 °C. The cells were collected by centrifugation, washed twice with sterile distilled water and standardized to 2x10⁶ cells/ml in SD broth by a spectrophotometric method using a standard curve.

**Antimicrobial drugs:** Cefepime (Sagent Pharmaceuticals, Schaumberg, IL, USA), imipenem and ciprofloxacin (Teva Parenteral Medicines, Inc., Irvine, CA, USA) were prepared into 1mg/ml stock solutions using sterile distilled water and stored at 0.25ml aliquots at -20 °C. The frozen stocks were thawed at room temperature and used within 24h. Antifungal drugs were obtained as pure powder from the manufacturers as follows: voriconazole and posaconazole were obtained from Pfizer Pharmaceuticals (New York, NY, USA) and Schering-Plough Research Institute (Kenilworth, NJ, USA), respectively. Amphotericin B was purchased from Sigma Chemical Company (St. Louis, MO, USA). Anidulafungin was obtained from Pfizer Pharmaceuticals, New York, NY, USA. The triazoles and amphotericin B were dissolved in DMSO to obtain a stock solution of 10mg/ml and subsequently diluted in 0.5% DMSO before use. Cefepime (Sagent Pharmaceuticals, New York, NY, USA) and Schering-Plough Research Institute (Kenilworth, NJ, USA), respectively. Amphotericin B was purchased from Sigma Chemical Company (St. Louis, MO, USA). Anidulafungin was obtained from Pfizer Pharmaceuticals, New York, NY, USA. The triazoles and amphotericin B were dissolved in DMSO to obtain a stock solution of 10mg/ml and stored as 0.25ml aliquots at -20 °C. The frozen stocks were thawed at room temperature and used within 24h. Antifungal drugs were obtained as pure powder from the manufacturers as follows: voriconazole and posaconazole were obtained from Pfizer Pharmaceuticals (New York, NY, USA) and Schering-Plough Research Institute (Kenilworth, NJ, USA), respectively. Amphotericin B was purchased from Sigma Chemical Company (St. Louis, MO, USA). Anidulafungin was obtained from Pfizer Pharmaceuticals, New York, NY, USA. The triazoles and amphotericin B were dissolved in DMSO to obtain a stock solution of 10mg/ml and subsequently diluted in 0.5% DMSO before use. Cefepime (Sagent Pharmaceuticals, New York, NY, USA) and Schering-Plough Research Institute (Kenilworth, NJ, USA), respectively. Amphotericin B was purchased from Sigma Chemical Company (St. Louis, MO, USA). Anidulafungin was obtained from Pfizer Pharmaceuticals, New York, NY, USA. The triazoles and amphotericin B were dissolved in DMSO to obtain a stock solution of 10mg/ml and stored as 0.25ml aliquots at -20 °C. The frozen stocks were thawed at room temperature and used within 24h. Where it is applicable, comparable concentrations of DMSO were used as control to examine its effect on the growth of the organism.

**Statistical analysis:** The data were analysed by Student’s t-test, one-way and two-way analysis of variance with Bonferroni’s Multiple Comparison Test using GraphPad Prism Version 5.0 for Windows (GraphPad Software, Inc., La Jolla, CA, USA). A p value
≤0.05 was considered significant. Details of each statistical test used are given in the corresponding figure legend.

Results

Characteristics of monomicrobial and polymicrobial biofilms: Figure 1 shows scanning electron microscopic images of 24h monomicrobial and polymicrobial biofilms of *A. fumigatus* and *P. aeruginosa*. As shown in panel A, *A. fumigatus* conidia readily adhered to the ThermaNox plastic coverslip and produced a confluent mycelial growth firmly attached to the plastic coverslip. Typically, lateral and apical dichotomous branching of hyphal filaments characteristic of *A. fumigatus* growing in rich medium appeared to be minimal and the hyphae extend by apical growth without branching. Bundles of parallel packed hyphal filaments (black arrow) held together by a fluffy extracellular matrix produced by the adhered hyphae (white arrows) were readily seen. In addition to the growing hyphae, ungerminated conidia and sporelings were also seen attached to the substrate as a result of non-synchronous spore germination and growth.

FIGURE 1: Scanning electron microscopic images of monomicrobial and polymicrobial biofilms of *A. fumigatus* and *P. aeruginosa*. The biofilms were grown on 13 mm sterile ThermaNox plastic cover slips in SD broth in 12-well Costar cell culture plates and processed for electron microscopy as previously described. Panel A: Germinating *A. fumigatus* conidia produced a firmly adhered mycelial growth on the plastic cover slips immersed in SD broth at the bottom of the cell culture plate. The mycelial growth mainly consists of unbranched hyphae often forming bundles of parallel packed hyphal filaments (black arrow). The parallel packed hyphal filaments were held together by a fluffy extracellular matrix produced by the adhered hyphae (white arrows). Panel B: Light microscopic image of a growing region of an *A. fumigatus* colony grown in a shake suspension culture showing numerous hyphal branches. Representatives of apical dichotomous and lateral hyphal branches are indicated by the black arrows. Panel C: *P. aeruginosa* formed a multilayer aggregate of cells seemingly held together by extracellular matrix and perhaps by surface appendages such as flagella and surface pili (fimbriae) (white arrow) not only among themselves but also to the substrate. The monomicrobial biofilm produced by *P. aeruginosa* was loosely adhered to the plastic cover slips and often dislodged by vigorous agitation. The extracellular matrix partially covering the cell surface was visible (black arrow) in 24-h *P. aeruginosa* biofilm. Panel D: Static coincubation of *A. fumigatus* sporelings pregrown for 12 h or longer with *P. aeruginosa* cells produced a mixed community of cells consisting of fungal hyphae and bacterial cells. The bacterial cells were embedded in a mesh like extracellular matrix material and firmly adhered to the plastic cover slips. The extracellular matrix (white arrows) production was significantly enhanced and the bacterial cells held together by the surface appendages are also firmly attached to the fungal hyphae using it as support (black arrows) to build the mixed microbial biofilm community. The adherent bacterial cells were hardly removed by vigorous agitation during extensive washing of the biofilm.

Since one of the characteristic features of the monomicrobial biofilm of *A. fumigatus* was the absence of hyphal branching we examined the branching pattern of AF43135 (one of the *A. fumigatus* isolates used in this study) in SD broth in planktonic shake and static cultures at 35 °C. As shown in panel B, in the planktonic shake and static cultures AF43135 produced branches (arrows) extensively usually either at the junctional point where the septum formation takes place (lateral branches) or at the apex of the hypha (dichotomous branching) producing secondary and tertiary branches forming a prolific network of mycelial growth.
Figure 1 panel C shows the general architecture of monomicrobial biofilm of P. aeruginosa formed on Thermanox plastic coverslip. P. aeruginosa formed a multilayer aggregate of cells seemingly held together perhaps by surface appendages such as flagella and surface pilus (fimbriae) (white arrow) and extracellular matrix not only among themselves but also to the substrate. The bulk of the monomicrobial biofilm produced by P. aeruginosa was loosely adhered to the Thermanox cover slips and was easily dislodged by vigorous agitation during extensive washing of the biofilm leaving a thin layer of cells firmly attached to the coverslips. The extracellular matrix partially covering the cell surface was visible (black arrow) in 24h P. aeruginosa biofilm.

Although the general appearance and architecture of the P. aeruginosa-A. fumigatus polymicrobial biofilm is similar to P. aeruginosa monomicrobial biofilm, the structure of the former was more complex. Inoculation of pregrown A. fumigatus mycelia adhered to Thermanox coverslip with P. aeruginosa cells produced a mixed community of cells consisting of fungal hyphae and bacterial cells (Figure 1 Panel D). The bacterial cells were embedded in a mesh-like extracellular matrix and firmly adhered to the coverslip using the fungal hyphae as scaffolding for firm adherence producing a prolific mixed microbial biofilm. Unlike the P. aeruginosa monomicrobial biofilm, the adherent bacterial cells in mixed microbial biofilm were not removed by extensive washing of the biofilm. The extracellular matrix (white arrows) production was significantly enhanced and the bacterial cells held together by the extracellular matrix as well as surface appendages were also firmly attached to the fungal hyphae using it as support (black arrows) to build the mixed microbial biofilm. In a 24h polymicrobial biofilm the matrix begins to encase the bacterial cells producing thicker biofilm. To evaluate the antibiotic susceptibilities of P. aeruginosa monomicrobial and Pa/Af polymicrobial biofilms we routinely used biofilms similar to the one shown in Figure 1.

Effects of antimicrobial drugs on biofilms: In vitro activities of cefepime, imipenem and ciprofloxacin individually and in two-drug combinations with four antifungal drugs, namely, voriconazole, posaconazole, amphotericin B and anidulafungin against monomicrobial and polymicrobial biofilms of Pa/Af were examined. Figure 2 shows the effects of voriconazole (panel A), posaconazole (panel B), amphotericin B (panel C) and anidulafungin (panel D) individually at 16µg/ml on A. fumigatus monomicrobial and Af/PA polymicrobial biofilms. Among various antifungal drugs used posaconazole showed the best activity (2.59 to 2.64 logs CFU reduction) against A. fumigatus biofilms whereas voriconazole (1.19 to 1.37 logs CFU reduction), amphotericin B (0.92 to 0.98 logs CFU reduction) and anidulafungin (0.64 to 0.83 logs CFU reduction) produced moderate to minimum effects compared to the drug-free control (p values ranged from 0.0033 to 0.0303). Regardless of the antifungal drug used, both the monomicrobial and the polymicrobial biofilm-associated A. fumigatus cells were almost equally susceptible to the inhibitory effects of the antifungal drugs alone (p values ranged from 0.1382 to 0.8265) or in combination with the antibacterial drugs cefepime, imipenem and ciprofloxacin (data not shown). However, a comparison of the fungicidal activities of various antifungal drugs against suspension cultures (see section on planktonic assay) and biofilms (Figure 2) showed that the latter was substantially less susceptible to antifungal drugs compared to planktonic cells.

Figure 2: Antifungal activities of voriconazole (A), posaconazole (B), amphotericin B (C) and anidulafungin (D) on AF35470 monomicrobial and AF53470-PAS6402 polymicrobial biofilms. The experiments were performed several times and the results shown here represent data from two independent experiments with three replications. Each histogram represents the mean of two independent experiments and the vertical bar on each histogram denotes the standard deviation. The data were analysed by pair-wise comparison of each group by Student’s t-test using Graphpad Prism 5.0 and a p value ≤0.05 was considered to be significant. The data shown in Figure 2 illustrate the activities of various antifungal drugs at a concentration of 16µg/ml. AF, A. fumigatus monomicrobial biofilm; AF-PA, A. fumigatus-P. aeruginosa polymicrobial biofilm; VRC, voriconazole; PCZ, posaconazole; AMB, amphotericin B; ANF, anidulafungin. In addition, the experiment was repeated twice with laboratory isolates AF35607 and PA27653 and similar results were obtained.

Citation: Manavathu EK, Vazquez JA (2015) Effects of Antimicrobial Combinations on Pseudomonas aeruginosa-Aspergillus fumigatus Mixed Microbial Biofilm. J Microbiol Exp 2(4): 00057. DOI: 10.15406/jmen.2015.02.00057
Figure 3 shows the effects of cefepime alone and in pairwise combination with voriconazole (panel A), amphotericin B (panel B) and anidulafungin (panel C) and imipenem alone and in combination with posaconazole (panel D) against \textit{P. aeruginosa} monomicrobial and \textit{Pa/Af} polymicrobial biofilms. A 24h exposure of \textit{P. aeruginosa} monomicrobial biofilm to 16µg/ml cefepime reduced CFU by 2.12 to 3.94 logs. The same concentration of cefepime reduced \textit{P. aeruginosa} CFU in mixed microbial biofilm by only 0 to 0.54 logs when compared to the drug free control, suggesting that polymicrobial biofilm embedded \textit{P. aeruginosa} cells were highly recalcitrant to the bactericidal activity of cefepime (\(p\) values ranged from 0.0076 to 0.0509). Similarly, evaluation of the effects of cefepime (16µg/ml) in two-drug combination with various antifungal drugs (16µg/ml) against \textit{P. aeruginosa} monomicrobial (0.94 to 4.5 logs CFU reduction) and polymicrobial (0 to 0.74 logs CFU reduction) biofilms showed that the latter was substantially less susceptible to the drug combinations, except for cefepime plus amphotericin B (\(p\) values ranged from 0.0141 to 0.1370).

However, a comparison of the effects of cefepime alone and in combination with various antifungal drugs against \textit{P. aeruginosa} monomicrobial (\(p\) values ranged from 0.3581 to 0.4294) and \textit{Pa/Af} (\(p\) values ranged from 0.0660 to 0.1702) biofilms showed no significant difference suggesting that the presence of the antifungal in combination did not affect the activity of cefepime. Panel D shows the effect of imipenem alone and in two-drug combination with posaconazole against monomicrobial and polymicrobial biofilms of \textit{P. aeruginosa} and \textit{A. fumigatus}. Unlike cefepime, the bactericidal activity of imipenem did not peak at 16µg/ml, but maximum effect was obtained at 64µg/ml. However, the \textit{Pa/Af} biofilm (\(<0.5\) logs CFU reduction) was significantly less susceptible to imipenem compared to its activity against monomicrobial biofilm (\(<1.5\) logs CFU reduction) (\(p=0.0492\)). The presence of posaconazole did not affect the activity of imipenem against \textit{P. aeruginosa} since its activity against polymicrobial biofilm alone and in combination with posaconazole showed no significant difference.

**Figure 3:** Effects of cefepime alone and in two-drug combinations with various antifungal drugs (Panels A-C) and imipenem alone and in combination with posaconazole (Panel D) against PA56402 monomicrobial and PA56402-AF53470 polymicrobial biofilms. The biofilms were formed in Costar 24-well cell culture plates and treated with various antimicrobial drug(s) for 24h at 35 °C in SD broth, washed and the numbers of CFU were determined by selective growth as previously described. The experiment was performed two times independently and the data were analysed by pair-wise two-tailed Student’s t-test and one-way ANOVA with Bonferroni’s post test comparison where each set of data was compared with all the other sets of data using Graphpad Prism 5.0. A \(p\) value \(<0.05\) was considered to be significant. The vertical bar on each data point denotes standard deviation of two independent experiments. In addition, the experiment was repeated twice with PAO1 and AF43135 and similar results were obtained. \textit{P. aeruginosa} monomicrobial biofilms; \textit{PA-AF}, \textit{P. aeruginosa-A. fumigatus} polymicrobial biofilms; \textit{VRC}, voriconazole; \textit{PCZ}, posaconazole; \textit{AMB}, amphotericin B; \textit{ANF}, anidulafungin; \textit{FEP}, cefepime; \textit{IMP}, imipenem.

Figure 4 shows the effects of ciprofloxacin alone and in two-drug combination with voriconazole (panel A), posaconazole (panel B), amphotericin B (panel C) and anidulafungin (panel D) against \textit{P. aeruginosa} monomicrobial and \textit{Pa/Af} polymicrobial biofilms. A 24h exposure of \textit{P. aeruginosa} monomicrobial biofilms to 16µg/ml ciprofloxacin reduced CFU by 2.58 to 4.65 logs, whereas the same concentration of ciprofloxacin reduced \textit{P. aeruginosa} CFU in \textit{Pa/Af} polymicrobial biofilms by 2.82 to 3.58 logs compared to the drug free control. This suggest that the monomicrobial and polymicrobial biofilm-embedded \textit{P. aeruginosa} cells were almost equally susceptible (\(p\) values ranged from 0.1095 to 0.4339) to the bactericidal activity of ciprofloxacin. Similarly, evaluation of ciprofloxacin (16µg/ml) in two-drug combination with various antifungal drugs (16µg/ml) against \textit{P. aeruginosa} monomicrobial (2.33 to 5.09 logs CFU reduction) and \textit{Pa/Af} (2.94 to 4.08 logs CFU reduction) biofilms showed that they were essentially equally susceptible (\(p\) values ranged from 0.1215 to 0.4314) to the drug combinations. In
addition, a comparison of the effects of ciprofloxacin alone and in two-drug combination with various antifungal drugs against *P. aeruginosa* monomicrobial (*p* values ranged from 0.1784 to 0.5835) and *P. aeruginosa*-A. fumigatus polymicrobial (*p* values ranged from 0.2150 to 0.912) biofilms showed no significant difference suggesting that the presence of the antifungal drug in the combination did not affect the activity of ciprofloxacin. Thus, the effects of ciprofloxacin alone and in combination with the antifungal drugs against *P. aeruginosa* monomicrobial and Pa/Af biofilms were markedly different than those seen with cefepime and imipenem alone and in combination with various antifungals. While the Pa/Af biofilm showed significantly lower susceptibility to cefepime and cefepime plus the antifungal drug combinations, both monomicrobial and Pa/Af biofilms were highly susceptible to ciprofloxacin alone and in two-drug combination with either voriconazole, posaconazole, amphotericin B and anidulafungin. The in vitro activity of the antifungal or the antibacterial drug was not affected in the presence of combination therapy, demonstrating that it is unlikely that there was any antagonistic interaction between the antibacterial and the antifungal agent.

**Effects of antimicrobial drugs on planktonic cells:** Figure 5 shows the bactericidal and fungicidal activities of various antimicrobial drugs individually and in two-drug combinations against monomicrobial and polymicrobial planktonic cultures of *Pa/Af*. Panel A shows the results of the CFU assay of the initial inoculum used for the experiment. The initial inoculum was standardized to 1x10⁶ cells/organism/ml in the monomicrobial and polymicrobial cell suspensions. The assay was performed immediately after the mixed cell suspensions were prepared. Both *P. aeruginosa* and *A. fumigatus* produced approximately 1x10⁶CFU/ml ± experimental errors. Therefore, any reduction in CFUs obtained after the drug treatment was not due to variation in the initial inoculum.

Panel B shows the growth of *P. aeruginosa* and *A. fumigatus* in the absence of antimicrobial drugs (drug-free control) for 24h at 35 °C in suspension cultures. *P. aeruginosa* and *A. fumigatus* produced the same level of growth in monocultures and in mixed cultures as determined by CFU assay. These results show that any reduction of CFU demonstrated in Panels C-F is unlikely to be due to antagonistic interactions between *P. aeruginosa* and *A. fumigatus*.

A comparison of the CFU values shown in Panels C-F with the initial cell density used for the kill curve experiments (1x10⁶ cells each/ml) showed that both cefepime and ciprofloxacin were highly effective in killing planktonic cells of *P. aeruginosa* (~4-5 logs reduction in CFU) in monomicrobial and polymicrobial planktonic cell suspensions. Similarly, the antifungal drugs voriconazole, posaconazole, amphotericin B and anidulafungin reduced CFU values on the average 3-4 logs except in the case of the echinocandin, anidulafungin, which is known to be a fungistatic drug against *A. fumigatus* and showed no significant activity. The presence of the antibacterial drug in the combination did not affect the activity of the antifungal drug and *vice versa*. Cefepime and ciprofloxacin provided more or less similar results in the presence of all four antifungal drugs used.

---

**Figure 4:** Effects of ciprofloxacin alone and in two-drug combinations with various antifungal drugs against PAS6402 monomicrobial and PA56402-AFS3470 polymicrobial biofilms. Each experiment was performed twice with PAS6402 and AFS3470 and once with the laboratory strains PA27853 and AF36607 (data not shown). The data were analysed by pair-wise two-tailed Student’s *t*-test and one-way ANOVA with Bonferroni’s post test comparison where each set of data was compared with all the other sets of data using Graphpad Prism 5.0, and a *p* value ≤0.05 was considered to be significant. The vertical bar on each data point denotes standard deviation of two independent experiments. Results obtained for PA27853 and AF36607 were very similar those shown in **Figure 4**. **PA:** *P. aeruginosa* monomicrobial biofilm; **PA-AF:** *P. aeruginosa-A. fumigatus* polymicrobial biofilm; **VRC:** voriconazole; **PCZ:** posaconazole; **AMB:** amphotericin B; **ANF:** anidulafungin; **CIP:** ciprofloxacin.
Figure 5: The microbicidal activities of various antimicrobial drugs individually and in two-drug combinations against monomicrobial and mixed microbial planktonic cultures of PA56402 and AF53470. **Panel A** shows the results of CFU assay for the initial inoculum. **Panel B** shows growth of the organism in monomicrobial and mixed microbial cultures in the absence of any antimicrobial drug (drug-free growth controls). **Panels C-F** shows the effects of various antimicrobial drugs alone (4 times MICs shown in Table 1) and in pair-wise combination against *P. aeruginosa* and *A. fumigatus* in monomicrobial and mixed microbial cultures. **FEP**, cefepime; **CIP**, ciprofloxacin; **VRC**, voriconazole; **PCZ**, posaconazole; **AMB**, amphotericin B; **ANF**, anidulafungin; **Pa**, *P. aeruginosa*; **Af**, *A. fumigatus*; **Pa-Af**: *P. aeruginosa* CFUs obtained in mixed cultures; **Pa-Af-Af**: *A. fumigatus* CFUs obtained in mixed cultures. Each histogram represents the mean of CFU values obtained for two independent experiments and the vertical bar denotes standard deviation. The reduction of CFUs compared to the initial inoculum ranged approximately from 4-5 logs for *P. aeruginosa* and 3-4 logs for *A. fumigatus* except for anidulafungin. All comparisons were highly significant (P≤0.001) except in the case of *A. fumigatus* CFU values in **Panel F** where the fungistatic drug anidulafungin is used. Pair-wise comparisons of the CFUs for each group were performed by Student’s t-test using Graphpad prism 5.0 for Windows (GraphPad Software, Inc., La Jolla, CA, USA). In addition, the experiment was repeated once with PAO1 and AF43135 and similar results were obtained.

Table 1: *In vitro* susceptibility of *Pseudomonas aeruginosa* 56402 and *Aspergillus fumigatus* 53470 to various antibacterial and antifungal drugs.

| Microorganism          | Antimicrobial drug | MIC (mg/L) |
|------------------------|-------------------|------------|
| *P. aeruginosa* 56402  | Amikacin          | ≤2         |
|                        | Cefepime          | ≤1         |
|                        | Ciprofloxacin     | ≤0.5       |
|                        | Gentamicin        | ≤1         |
|                        | Imipenem          | 2          |
|                        | Piperacillin/tazobactam | 8        |
|                        | Tobramycin        | ≤1         |
| *A. fumigatus* 53470   | Voriconazole      | 0.25       |
|                        | Posaconazole      | 0.125      |
|                        | Caspofungin       | 0.031*     |
|                        | Micafungin        | 0.031*     |
|                        | Anidulafungin     | 0.031*     |
|                        | Amphotericin B    | 1          |

*Values represent minimum effective concentration.
Discussion

Our prior studies evaluating the formation and antimicrobial drug susceptibilities of monomicrobial and polymicrobial biofilms of *A. fumigatus* and *P. aeruginosa* indicated that *A. fumigatus* and *P. aeruginosa* are capable of co-existing in a sustainable manner in mixed microbial cultures in vitro. Microscopic examination of the monomicrobial and polymicrobial biofilms showed that *P. aeruginosa* produced a dense, more adherent biofilm in the presence of *A. fumigatus* hyphae. In part, this is due to the fungal hyphae supporting the polymicrobial biofilm production. In our recent studies using SEM, we were able to confirm our previous observations by light microscopy and revealed the presence of thicker biofilms in cocultures of *Pa/Af* demonstrating a firmly adhered mycelial growth as scaffolding to support the synthesis of a densely packed extracellular matrix that encases the bacterial cells. However, it is highly likely that other contributing genetic factors are in play assisting in the increased synthesis of extracellular matrix.

One of the characteristic features of the monomicrobial biofilm of *A. fumigatus* is the absence of hyphal branching. In the planktonic shaken or static cultures, *A. fumigatus* hyphae branch extensively either at the functional point where the septum formation takes place or at the growing apical region of the hypha, producing secondary and tertiary branches forming a prolific network of mycelial growth. In contrast, the firmly adherent extensive mycelial growth in biofilm cultures seldom produces any branches and the hyphae extend by apical growth and forms bundles of parallel packed hyphal filaments fused together apparently by the extracellular.

The absence of branch formation is an intriguing observation for an organism usually thrives by producing primary and secondary branches. Branching takes place in the presence of plenty of nutrients during prolific vegetative growth conditions for the rapid expansion of fungal growth and establishes rapid infection in the case of a pathogenic organism. In contrast, during starvation or in the absence of nutrients the fungus resorts to have fewer branching, non-proliferative growth and exists in a so-called ‘maintenance mode’ as opposed to active growth. Microbial biofilms are commonly produced under conditions of chronic or long-term infection not during active infection. Thus, under chronic infectious stage the microorganisms may be in the so-called ‘maintenance mode’ equipping them for survival. Therefore, it is not surprising that the fungal hyphae are not branching out vigorously under biofilm producing condition since it is functionally analogous to a state of chronicity.

Four commonly used antifungal drugs and three antibacterial drugs known to have excellent activity against *P. aeruginosa* were used in this study. We used the CFU assay for measuring the effectiveness of various antifungal drugs on the monomicrobial and polymicrobial biofilms of *A. fumigatus* and *P. aeruginosa*. The other techniques such as XTT [57,58], and MTT [59,60] assays previously used for the evaluation of the effectiveness of antifungal drug treatment were unsuitable in these experiments because of the difficulty for distinguishing the contribution of the bacterial and the fungal cells of the polymicrobial biofilm in the reduction of the tetrazolium compound. On the other hand, since the CFU assay was based on selective growth of the bacterial and fungal cells after drug treatment, the results provided a more refined effect of the drugs on *A. fumigatus* and *P. aeruginosa*. The drawback of the CFU assay was that the hyphal form of *A. fumigatus* produced a high variability. This is primarily because of the tendency of the fungal hyphae for clumping and the fact that the presumed “one fungal colony for one hyphal element principle” does not apply and often results in under estimation of the CFU values. Additionally, since the clumping is a random phenomenon, high variability between replicates was commonly seen. To minimize the impact of possible poor replication and a possible under estimation of the fungal CFU values on the results, we repeated each experiment several times.

Our previous preliminary studies on the effects of the triazole antifungal drugs on the fungal constituent of the polymicrobial biofilm showed no significant change in its susceptibility compared to that in monomicrobial biofilm. In these studies, in addition to voriconazole and posaconazole, members of the polyene and the echinocandin families were evaluated. Results of this study not only confirmed our previous finding, but also demonstrate that the lack of differential susceptibility of *A. fumigatus* in polymicrobial biofilm is not limited to triazoles, but is also true for amphotericin B and anidulafungin, different classes of antifungals. There may be several reasons for the apparent lack of effect on the fungal hyphae including the quiescent nature of the hyphae in the biofilm and the pluripotent ability of the hyphae of filamentous fungi.

Among the four antifungal drugs used, posaconazole showed the best activity against monomicrobial and polymicrobial biofilms of *A. fumigatus*. However, in contrast to the excellent activity of posaconazole against conidia, sporelings and planktonic hyphae, the adherent mycelia were less susceptible to the fungicidal activity of posaconazole. Overall, anidulafungin showed the least fungicidal activity against the monomicrobial and polymicrobial biofilms of *A. fumigatus*. This is not surprising considering the fact that the echinocandins are known to be fungistatic agents against filamentous fungi such as *A. fumigatus*, and elicit their action on the apices of growing fungal hyphae by inhibiting the synthesis of new cell wall. Although anidulafungin inhibits the growth of the fungal hyphae, its inhibitory action precludes any fungicidal effect on the vegetative hyphae. Since mature fungal hyphae have the ability to grow and form new colonies, anidulafungin showed very little effect on the CFU’s of monomicrobial and polymicrobial biofilms of *A. fumigatus*. This observation also suggests that the reduction in fungal CFU may reflect fungicidal activity of the drug (not inhibition of fungal growth) since the triazoles and the polyenes are fungicidal for *A. fumigatus* [61]. A comparison of the *in vitro* activities of several antifungals against *A. fumigatus* monomicrobial and Af/Pa biofilms showed no significant difference. Monomicrobial and mixed microbial cultures of *A. fumigatus* with *P. aeruginosa* were almost equally susceptible to the fungicidal activities of the antifungal drugs. Overall, 1 - 1.5 log CFU reductions were obtained after a 24h exposure to different drugs. Similarly, a comparison of the effect of the antifungal drug alone or in combination with the antibacterial drug showed similar fungicidal activities indicating that there was no *in vitro* drug-drug interaction affecting their activities.

In contrast to the similar susceptibilities of monomicrobial and polymicrobial biofilms of *A. fumigatus* to various antifungal drugs, the Pa/Af biofilm was substantially less susceptible to the
antibacterial effect of ceftime and imipenem when compared to *P. aeruginosa* monomicrobial biofilm, although *P. aeruginosa* isolates were susceptible to ceftime and imipenem in planktonic cultures. This differential susceptibility of the monomicrobial and polymicrobial biofilms of *P. aeruginosa* to ceftime and imipenem was not seen when the biofilms were exposed to ciprofloxacin. At the highest drug concentration after a 24h exposure, both monomicrobial and polymicrobial biofilm-bound *P. aeruginosa* cells were killed almost to the same extent suggesting that certain combinations of drugs are more effective against biofilm-embedded cells than others.

In conclusion, using a previously developed 24-well cell culture plate biofilm model we investigated the antimicrobial activities of ceftime, imipenem and ciprofloxacin individually and in two-drug combinations with four antifungal drugs against monomicrobial and polymicrobial biofilms of three isolates of *P. aeruginosa* and *A. fumigatus*. Both *A. fumigatus* monomicrobial and Pa/Af biofilms were equally susceptible to the antifungal drugs with and without the antibacterial drugs. On the other hand, the *P. aeruginosa* monomicrobial and Pa/Af biofilms were almost equally susceptible to ciprofloxacin in the presence and absence of the antifungal drugs, whereas the Pa/Af biofilm complex was less susceptible to ceftime and imipenem than the *P. aeruginosa* in monomicrobial biofilm.

Overall, we describe that the susceptibility of *A. fumigatus* cells to the antifungal drugs remained almost the same in monomicrobial and polymicrobial biofilms. On the other hand, the susceptibility of polymicrobial biofilm-bound *P. aeruginosa* cells to ceftime and imipenem, but not to ciprofloxacin, was significantly reduced compared to the activity seen in monomicrobial biofilms.

Acknowledgment

The authors would like thank Dora Vager for her excellent technical assistance. Parts of the results included in this manuscript were previously presented at the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2011 (Abstract M-308).

Funding

This work was supported by Intramural Research Initiative from the Department of Medicine, Georgia Regents University, Augusta, Georgia, USA.

Transparency Declarations

The authors report no conflicts of interest. The authors alone are responsible for the content and the writing of the paper.

References

1. Zemanick ET, Sagel SD, Harris JK (2015) The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr 23(3): 319-324.

2. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, et al. (2010) Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 5(6): e11044.

3. Rogers GB, Carroll MP, Hoffman LR, Walker AW, Fine DA, et al. (2011) Comparing the microbiota of the cystic fibrosis lung and human gut. Gut Microbes 1(2): 85-93.

4. van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, et al. (2010) Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J 5(5): 780-791.

5. Guss AM, Roeselers G, Newton IL, Young CR, Klepac-Ceraj V, et al. (2011) Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J 5(1): 20-29.

6. Rogers GB, Carrill MP, Serisier DJ, Hockey PM, Jones G, et al. (2004) Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 42(11): 5176-5183.

7. Boucham JP, Hsieh HY, Croquerer S, Barton R, Marchais V, et al. (2009) Development of an oligonucleotide array for direct detection of fungi in sputum samples from patients with cystic fibrosis. J Clin Microbiol 47(1): 142-152.

8. Bittr F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremler N, et al. (2008) Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 3(8): e2908.

9. Zemanick ET, Wagner BD, Sagel SD, Stevens MJ, Accurro FL, et al. (2010) Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimens. PLoS One 5(11): e15101.

10. Rogers GB, Daniels TW, Tuck A, Carroll MP, Connell GJ, et al. (2009) Studying bacteria in respiratory specimens by using conventional and molecular microbiological approaches. BMC Pulm Med 9: 14.

11. Lipuma JJ (2010) The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 23(2): 299-323.

12. Valenza G, Tappe D, Turnwald D, Frosch M, Konig C, et al. (2008) Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 7(2): 123-127.

13. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, et al. (2009) Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 132(6): 1554-1560.

14. Oliver A, Alarcon T, Caballero E, Canton R (2009) Microbiological diagnosis of bronchopulmonary colonization-infection in cystic fibrosis. Enferm Infec Microbiol Clin 27(2): 89-104. [Article in Spanish].

15. Foundation CF (2008) Patient Registry 2008. Annual data report to the center directors. Cystic Fibrosis Foundation, Bethesda, MD, USA.

16. Paugam A, Baixench MT, Domazet-Duciu N, Burgel PR, Sauter E, et al. (2010) Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 48(Suppl 1): S32-S36.

17. Hauser AR, Jain M, Bar-Meir M, McColley SA (2011) Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 24(1): 29-70.

18. Amin R, Dupuis A, Aaron SD, Ratjen F (2010) The effect of chronic infection with *Aspergillus fumigatus* on lung function and hospitalization in patients with cystic fibrosis. Chest 137(1): 171-176.

19. Pihet M, Carrere J, Cimon B, Chatasse D, DELhaes L, et al. (2009) Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis—a review. Med Mycol 47(4): 387-397.

20. Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP (2010) Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros 9(2): 110-116.
Effects of Antimicrobial Combinations on *Pseudomonas aeruginosa-Aspergillus fumigatus* Mixed Microbial Biofilm

21. Bakane N, Rickerts V, Bargon J, Just-Nubling G (2003) Prevalence of *Aspergillus fumigatus* and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 46(1-2): 19-23.

22. Webb AK, Woolnough E (2006) *Candida albicans* infection in adults with cystic fibrosis. J R Soc Med 99(Suppl 46): 13-16.

23. Chotirmall SH, Greene CM, McElvaney NG (2010) *Candida* species in cystic fibrosis: A road less travelled. Med Mycol 48(Suppl 1): S114-S124.

24. Gammelsrud KW, Sandven P, Holby EA, Sandvik L, Brandtzaeg P, et al. (2011) Colonization by *Candida* in children with cancer, children with cystic fibrosis, and healthy controls. Clin Microbiol Infect 17(12): 1875-1881.

25. Muthig M, Hebestreit A, Ziegler U, Seidler M, Muller FM (2010) Persistence of *Candida* species in the respiratory tract of cystic fibrosis patients. Med Mycol 48(1): 56-63.

26. Chotirmall SH, O’Donoghue E, Bennett K, Gunantrnam C, O’Neill SJ, et al. (2010) Sputum *Candida albicans* presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis. Chest 138(5): 1186-1195.

27. Harun A, Gilgado F, Chen SC, Meyer W (2010) Abundance of *Pseudallescheria/Scedosporium* species in the Australian urban environment suggests a possible source for scedosporiosis including the colonization of airways in cystic fibrosis. Med Mycol 48(Suppl 1): S70-S76.

28. Blyth CC, Middleton PG, Harun A, Sorrell TC, Meyer W, et al. (2010) Clinical associations and prevalence of *Scedosporium spp.* in Australian cystic fibrosis patients: identification of novel risk factors? Med Mycol 48(Suppl 1): S37-S44.

29. Cimon B, Carrere J, Vinatier JP, Chazalette JP, Chabasse D, et al. (2000) Clinical significance of *Scedosporium apiospermum* in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 19(1): 53-56.

30. Horre R, Marklein G (2009) Isolation and clinical significance of *Pseudallescheria* and *Scedosporium* species. Med Mycol 47(4): 415-421.

31. Lebecque P, Leonard A, Huang D, Reycher G, Boeiras A, et al. (2010) *Exophiala* (Wangiella) dermatitidis and cystic fibrosis - Prevalence and risk factors. Med Mycol 48(Suppl 1): S45-S54.

32. Kondori N, Gilljam M, Lindblad A, Jonsson B, Moore ER, et al. (2011) High rate of *Exophiala dermatitidis* recovery in the airways of patients with cystic fibrosis is associated with pancreatic insufficiency. J Clin Microbiol 49(3): 1004-1009.

33. Griffard EA, Guajardo JR, Cooperstock MS, Scoville CL (2010) Isolation of *Exophiala dermatitidis* from pigmented sputum in a cystic fibrosis patient. Pediatr Pulmonol 45(5): 508-510.

34. Horre R, Schaal KP, Skiemeyer R, Sterzik B, de Hoog GS, et al. (2004) Isolation of fungi, especially *Exophiala dermatitidis*, in patients suffering from cystic fibrosis. A prospective study. Respiration 71(4): 360-366.

35. Montes-Cano MA, de la Horra C, Dapena FJ, Mateos I, Frizera V, et al. (2007) Dynamic colonisation by different *Pneumocystis jirovecii* genotypes in cysic fibrosis patients. Clin Microbiol Infect 13(10): 1009-1011.

36. Royce FH, Blumberg DA (2000) *Pneumocystis carinii* isolated from lung lavage fluid in an infant with cystic fibrosis. Pediatr Pulmonol 29(3): 235-239.

37. Gal SL, Heriy-Arnau G, Ramel S, Vermaux M, Damiani C, et al. (2010) *Pneumocystis jirovecii* and cystic fibrosis in France. Scand J Infect Dis 42(3): 225-227.

38. Respaldiza N, Montes-Can MA, Dapena FJ, de la Horra C, Mateos I, et al. (2005) Prevalence of colonisation and genotypic characterisation of *Pneumocystis jiroveci* among cystic fibrosis patients in Spain. Clin Microbiol Infect 11(12): 1012-1015.

39. Leclair UW, Hogan DA (2010) Mixed bacterial-fungal infections in the CF respiratory tract. Med Mycol 48(Suppl 1): S215-S212.

40. Manavathu EK, Vazquez JA (2014) Development and antimicrobial susceptibility studies of *in vitro* monomicrobial and polymeric biofilm models with *Aspergillus fumigatus* and *Pseudomonas aeruginosa*. BMC Microbiol 14: 53.

41. Muller FM, Seidler M, Beuvais A (2011) *Aspergillus fumigatus* biofilms in the clinical setting. Med Mycol 49(Suppl 1): S96-S100.

42. Tomlin KL, Coll OP, Ciri H (2001) Interspecies biofilms of *Pseudomonas aeruginosa* and *Burkholderia cepacia*. Can J Microbiol 47(10): 949-954.

43. Wagner VE, Iglewski BH (2008) *P. aeruginosa* Biofilms in CF Infection. Clin Rev Allergy Immunol 35(3): 124-134.

44. Holby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, et al. (2001) *Pseudomonas aeruginosa* and the in vitro and in vivo biofilm mode of growth. Microbes Infect 3(1): 23-35.

45. Hill D, Rose B, Pajkos A, Robinson M, Bye P, et al. (2005) Antibiotic susceptibilities of *Pseudomonas aeruginosa* isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 43(10): 5085-5090.

46. Manno G, Cruciani M, Romano S, Scalopano S, Mentasti M, et al. (2005) Antimicrobial use and *Pseudomonas aeruginosa* susceptibility profile in a cystic fibrosis centre. Int J Antimicrob Agents 25(3): 195-197.

47. Islam S, Oh H, Jalal S, Karpati E, Ciofu O, et al. (2009) Chromosomal mechanisms of aminoglycoside resistance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. Clin Microbiol Infect 15(3): 60-66.

48. Fricks-Lima J, Hendrickson CM, Allgater M, Zhao H, Wiener-Kronish JP, et al. (2011) Differences in biofilm formation and antimicrobial resistance of *Pseudomonas aeruginosa* isolates from airways of mechanically ventilated patients and cystic fibrosis patients. Int J Antimicrob Agents 37(4): 309-315.

49. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, et al. (2003) A genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. Nature 426(6964): 306-310.

50. Ferrein AG, Leao RS, Carvalho-Assa AP, Folescu TW, Barth AL, et al. (2010) Influence of biofilm formation in the susceptibility of *Pseudomonas aeruginosa* from Brazilian patients with cystic fibrosis. APMS 118(8): 606-612.

51. Seidler MJ, Salvenmoser S, Muller FM (2008) *Aspergillus fumigatus* forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Agents Chemother 52(11): 4130-4136.

52. Mowat E, Butcher J, Lang S, Williams C, Ramage G (2007) Development of a simple model for studying the effects of antifungal agents on multicellular communities of *Aspergillus fumigatus*. J Med Microbiol 56(Pt 9): 1205-1212.

53. Mowat E, Lang S, Williams C, McCulloch E, Jones B, et al. (2008) Phase-dependent antifungal activity against *Aspergillus fumigatus* developing multicellular filamentous biofilms. J Antimicrob Chemother 62(6): 1281-1284.

54. http://www.spotimaging.com/

55. GLSI (2009) Performance Standards for antimicrobial susceptibility Testing: M100-S19, clinical and Laboratory Standards Institute, Wayne, PA, USA.
56. CLSI (2002) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard M-38A2. Clinical Laboratory Standards Institute, Wayne, PA, USA.

57. Tunney MM, Ramage G, Field TR, Moriarty TF, Storey DG (2004) Rapid colorimetric assay for antimicrobial susceptibility testing of Pseudomonas aeruginosa. Antimicrob Agents Chemother 48(5): 1879-1881.

58. Antachopoulos C, Meletiadis J, Roilides E, Sein T, Walsh TJ (2006) Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol 44(2): 553-560.

59. Meletiadis J, Meis JF, Mouton JW, Donnelly JP, Verweij PE (2000) Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 38(8): 2949-2954.

60. Levitz SM, Diamond RD (1985) A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J Infect Dis 152(5): 938-945.

61. Ryder NS, Leitner I (2001) Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 39(1): 91-95.